The company's services will be white labeled under the hospital system’s brand.
Teladoc Health ($TDOC) announced today that it struck a deal with Northwell Health to provide its Microsoft-compatiable telehealth technology to the large New York metro area healthcare system.
Teladoc has deals with other healthcare systems, but a company spokesperson said this is the first to involve Solo, its product that works with Microsoft Teams. Microsoft's teleconferencing software.
The deal, the terms of which were not disclosed, does not involve the services of clinicians that work for Teladoc. Instead, the company's telehealth technology will be “white labeled” under the Northwell Health brand and Northwell clinicians will use it to provide telehealth services to their patients.
Northwell Health, headquartered in New Hyde Park, New York, bills itself as New York State’s largest healthcare provider. The system comprises 22 hospitals, including North Shore University Hospital and Long Island Jewish Medical Center.
Teladoc’s stock was trading at $58.32 when the markets closed today, slightly down from its opening price of $59.79.
Teladoc announced in July 2021 that it had developed a product called Solo that works with Microsoft Teams, a software platform that supports teleconferencing like Zoom but also has direct messaging and scheduling functions.
FDA Updates for Week of May 13: First Bispecific Antibody for Solid Tumor
May 18th 2024The FDA has approved a new type of bispecific antibody to treat small cell lung cancer and an additional indication for Breyanzi for patients with follicular lymphoma. The agency has set review date for gene therapy for enzyme deficiency. In addition, Biogen have Eisai hve begun a rolling submission of subcutaneous Leqembi for Alzheimer’s disease.
Read More
Omega-3s For Dry Eye Disease? Not the Answer According to This Study
May 17th 2024Some research has suggested that omega-3 fatty acid supplements could help treat dry eye disease. But Korean investigators reported results from a randomized clinical trial this week in JAMA Ophthalmology tthat showed no benefit.
Read More